Author Bios

Ms. Smith is a fourth-year medical student at Wayne State University School of Medicine, Detroit, MI. Dr. Narla is a dermatology resident physician, in the Department of Dermatology, St. Luke’s Hospital, Easton, PA. Dr. Lyons is a dermatology resident physician, and Dr. Hamzavi is a senior staff physician, both in the Department of Dermatology, Henry Ford Hospital, Detroit, MI. Dr. Kohli is a clinical researcher and physicist in the Department of Dermatology, Henry Ford Hospital and adjunct faculty in the Department of Physics & Astronomy, Wayne State University, Detroit, MI. Dr. Siddiqui is vice chair, Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI. Dr. Rao is a professor of dermatology and pathology, in the Department of Dermatology, Robert Wood Johnson Medical School, Rutgers University, Somerset, NJ. Dr. Penman is at Oakland University, Rochester, MI.

Disclosure/informed consent: None of the authors received outside funding for the production of this original manuscript. Dr. Lyons is a subinvestigator for Incyte, Bayer, Unigen Inc., Lenicura, Estée Lauder, Miragen, Biofrontera, and L’Oréal. Dr. Narla is a subinvestigator for Incyte, Lenicura, L’Oréal, Pfizer, and Biofrontera. Dr. Kohli is a subinvestigator for Bayer, Estée Lauder, Unigen Inc., Ferndale laboratories, L’Oréal, Allergan, Johnson & Johnson, Chromaderm, and Pfizer. Dr. Siddiqui receives honoraria from Varian for guest lectures. Dr. Hamzavi is an investigator for Unigen Inc., Allergan, Clinuvel, Galderma, L’Oréal, PCORI, Pfizer, Incyte Corporation, Bayer, Estée Lauder, Ferndale Healthcare Inc., Lenicura, General Electric, Janssen Biotech, and Johnson & Johnson. He is also the co-chair of the Global Vitiligo Foundation (unpaid), is on AbbVie advisory board (unpaid), and is a consultant for Incyte. The remaining authors have no relevant conflicts of interest to declare. Prior Publication/Presentation: 1). Oral Presentation at the 2nd Scientific American Confocal Group meeting; March 19, 2020; Virtual. 2). Superficial Radiotherapy for Resistant Disseminated Superficial Actinic Porokeratosis. Abstract accepted for poster presentation at: the Photodermatology Society Annual Meeting; March 19, 2020; Cancelled due to COVID-19. The patient has provided informed consent for the publication of this case report.